The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson’s Disease

Trimetazidine is contraindicated in movement disorders, however, a not negligible part of trimetazidine users is still patients with Parkinson’s disease (PD). The present study aimed to objectively determine the impact of trimetazidine on the severity of symptoms and the health-related quality of li...

Descripción completa

Detalles Bibliográficos
Autores principales: Pintér, Dávid, Juhász, Annamária, Harmat, Márk, Janszky, József, Kovács, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308301/
https://www.ncbi.nlm.nih.gov/pubmed/32572075
http://dx.doi.org/10.1038/s41598-020-66692-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308301/
https://www.ncbi.nlm.nih.gov/pubmed/32572075
http://dx.doi.org/10.1038/s41598-020-66692-5

Ejemplares similares